Akebia Lowered Auryxia Product Revenue Guidance To $170M-$175M For FY23 From $175M-$180M Due To An Unfavorable Impact From Market Dynamics, Volume And Payor Mix
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has reduced its revenue guidance for its Auryxia product for FY23 from $175M-$180M to $170M-$175M. The revision is due to unfavorable market dynamics, volume, and payor mix.
September 26, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akebia Therapeutics has lowered its FY23 revenue guidance for its Auryxia product, which could negatively impact its stock price.
Akebia Therapeutics has lowered its revenue guidance for its Auryxia product for FY23. This indicates that the company expects lower sales than previously anticipated, which could negatively impact its financial performance and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100